These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25160521)

  • 21. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
    Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
    Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
    Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
    Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
    BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.
    Wong MK; Jonasch E; Pal SK; Signorovitch JE; Lin PL; Wang X; Liu Z; Culver K; Scott JA; George DJ; Vogelzang NJ
    Expert Opin Pharmacother; 2015 Apr; 16(6):805-19. PubMed ID: 25766864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
    BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.
    Porta C; Giglione P; Paglino C
    Expert Opin Pharmacother; 2016; 17(5):643-55. PubMed ID: 26630127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
    Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma.
    Santoni M; De Giorgi U; Iacovelli R; Conti A; Burattini L; Rossi L; Luca Burgio S; Berardi R; Muzzonigro G; Cortesi E; Amadori D; Cascinu S
    Br J Cancer; 2013 Oct; 109(7):1755-9. PubMed ID: 24008663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
    Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
    Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
    Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
    Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.